{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:17:22Z","timestamp":1787771842484,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Contrast-induced nephropathy (CIN) is associated with increased mortality and morbidity in patients undergoing coronary angiography (CAG) and percutaneous coronary intervention. This study aimed to compare the incidence of CIN in two groups of patients with and without metabolic syndrome (Mets) with baseline normal renal function.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n In this case \u2212 control study, 260 patient candidates for CAG, 130 patients with Mets and 130 patients without Mets participated, and their serum creatinine (Cr) level before and the 48 and 72 h after the angiography was measured. The incidence of CIN was compared in two groups. Two-way analysis of variance with repeated measures and univariate and multivariate logistic regression models.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The results showed a higher chance of being Mets with raising in triglyceride (adjusted odds ratio = 1.05, 95% confidence interval = (1.03\u20131.06),\n P<\/jats:italic>\n < 0.001), Fasting blood glucose (1.010 [1.001\u20131.019],\n P<\/jats:italic>\n = 0.025), and diastolic blood pressure (1.07 [1.07\u20131.20],\n P<\/jats:italic>\n < 0.001), but declining in high-density lipoprotein-cholesterol (HDL-C) (0.91 [0.85\u20130.98],\n P<\/jats:italic>\n = 0.008). Furthermore, blood urea nitrogen (BUN) and Cr level was raised in 48 and 72 h after contrast injection in both groups (All\n P<\/jats:italic>\n < 0.001). Furthermore, in 48 h (3.11 [1.12\u20139.93],\n P<\/jats:italic>\n = 0.016) and 72 h (2.82 [1.07\u20138.28],\n P<\/jats:italic>\n = 0.021) after injection, a total of 25 patients had an increased Cr level and a significant difference between Mets and without Mets groups. The developing Mets had a significant association with the increased risk of AKI, which increased the chance of developing nephropathy (7.14 [2.27\u201322.5],\n P<\/jats:italic>\n = 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Mets, together with other risk factors, increased the overall risk of CIN development. Therefore, the incidence of CIN in patients Mets is significantly higher than that of patients without Mets, indicating a more important CIN risk factor.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jrms.jrms_136_21","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:45Z","timestamp":1706745645000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?"],"prefix":"10.4103","volume":"29","author":[{"given":"Hasan","family":"Shemirani","sequence":"first","affiliation":[{"name":"Cardiology Department, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute and Chamran Cardiovascular and Medical Research Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Chamran Cardiovascular and Medical Research Hospital and Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/heartjnl-2014-306962","article-title":"Contrast-induced nephropathy following angiography and cardiac interventions","volume":"102","author":"Rear","year":"2016","journal-title":"Heart"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00330-017-5246-5","article-title":"Post-contrast acute kidney injury \u2013Part 1:Definition, clinical features, Incidence, role of contrast medium and risk factors:Recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9343(97)00150-2","article-title":"Acute renal failure after coronary intervention:Incidence, risk factors, and relationship to mortality","volume":"103","author":"McCullough","year":"1997","journal-title":"Am J Med"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/01.CIR.0000016043.87291.33","article-title":"Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention","volume":"105","author":"Rihal","year":"2002","journal-title":"Circulation"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2013.06.016","article-title":"Contemporary Incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions:insights from the NCDR cath-PCI registry","volume":"7","author":"Tsai","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"R6-20240830","first-page":"1","article-title":"The controversy of contrast-induced nephropathy with intravenous contrast:What is the risk?","volume":"20","author":"Rudnick","year":"2019","journal-title":"AJKD"},{"key":"R7-20240830","first-page":"226","article-title":"Nefropat\u00eda por medio de contraste en angiograf\u00eda cardiaca","volume":"26","author":"Valdez","year":"2010","journal-title":"Med Int Mex"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.medcli.2010.01.035","article-title":"Nefropat\u00eda inducida por contraste enpacientes de riesgo con insuficiencia renal explorados con tomograf\u00eda computarizada:Revisi\u00f3n sistem\u00e1tica ymeta an\u00e1lisis de ensayos cl\u00ednicos aleatorizados","volume":"135","author":"Arana","year":"2010","journal-title":"MedClin Barc"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2014.09.041","article-title":"Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention","volume":"106","author":"Barbieri","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00592-011-0309-6","article-title":"Metabolic syndrome:Its history, mechanisms, and limitations","volume":"49","author":"Oda","year":"2012","journal-title":"Acta Diabetol"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000092481","article-title":"Mets as a risk factor for contrast-induced nephropathy in nondiabetic elderly patients with renal impairment","volume":"29","author":"Toprak","year":"2006","journal-title":"Kidney Blood Press Res"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jama.289.5.553","article-title":"Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention:A randomized controlled trial","volume":"289","author":"Kay","year":"2003","journal-title":"JAMA"},{"key":"R13-20240830","first-page":"177","article-title":"Contrast-Induced Nephropathy (CIN) consensus working panel:Executive summary","volume":"7","author":"McCullough","year":"2006","journal-title":"Rev Cardiovasc Med"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11154-013-9268-2","article-title":"Metabolic syndrome and associated chronic kidney diseases:Nutritional interventions","volume":"14","author":"Kumar","year":"2013","journal-title":"Rev Endocr Metab Disord"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1681\/ASN.2005060638","article-title":"Obesity and risk for chronic renal failure","volume":"17","author":"Ejerblad","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"R\u00fcster","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ecl.2004.03.002","article-title":"The metabolic syndrome or the insulin resistance syndrome?Different names, different concepts, and different goals","volume":"33","author":"Reaven","year":"2004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.0000158483.13093.9D","article-title":"Mets:A comprehensive perspective based on interactions between obesity, diabetes, and inflammation","volume":"111","author":"Dandona","year":"2005","journal-title":"Circulation"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1051-2276(04)00133-5","article-title":"Association of obesity with inflammation in chronic kidney disease:A cross-sectional study","volume":"14","author":"Ramkumar","year":"2004","journal-title":"J Ren Nutr"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease:Global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/ndt\/gfl636","article-title":"Impact of diabetic and prediabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease","volume":"22","author":"Toprak","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.0000158483.13093.9D","article-title":"Mets:Acomprehensive perspective based on interactions between obesity, diabetes, and inflammation","volume":"111","author":"Dandona","year":"2005","journal-title":"Circulation"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jacc.2007.12.035","article-title":"Contrast-induced acute kidney injury","volume":"51","author":"McCullough","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R24-20240830","first-page":"1393","article-title":"Asimple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention:Development and initial validation","volume":"44","author":"Mehran","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000351985","article-title":"Dyslipidemia in patients with chronic and end-stage kidney disease","volume":"3","author":"Omran","year":"2013","journal-title":"Cardiorenal Med"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000075925","article-title":"Cellular lipid metabolism and the role of lipids in progressive renal disease","volume":"24","author":"Abrass","year":"2004","journal-title":"Am J Nephrol"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s00330-011-2371-4","article-title":"Are intravenous injections of contrast media really less nephrotoxic than intra-arterial injections?","volume":"22","author":"Nyman","year":"2012","journal-title":"Eur Radiol"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.juro.2007.08.054","article-title":"Conflicting and new risk factors for contrast induced nephropathy","volume":"178","author":"Toprak","year":"2007","journal-title":"J Urol"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MAJ.0b013e318068ddf9","article-title":"Risk markers for contrast-induced nephropathy","volume":"334","author":"Toprak","year":"2007","journal-title":"Am J Med Sci"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/clc.22364","article-title":"Impact of Mets on development of contrast-induced nephropathy after elective percutaneous coronary intervention among nondiabetic patients","volume":"38","author":"Ozcan","year":"2015","journal-title":"Clin Cardiol"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_136_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:17:19Z","timestamp":1787768239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jrms.jrms_136_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jrms.jrms_136_21","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2021-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}